经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析.pdf

《经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、介入放射学杂志2014年6月第23卷第6期JInterventRadiol2014，Vo1．23，No．6．——477．——·肿瘤介入Tumorintervention·经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析万豪光，许伟，徐浩，顾玉明，祖茂衡，王勇，宗迎迎【摘要】目的探讨经导管肝动脉化疗栓塞(TACE)联合经皮微波消融术(MWA)治疗中晚期肝癌预后的影响因素。方法2011年1月一20l2年7月，64例中晚期肝癌患者行TACE联合MWA治疗，收集14项可能影响预后的因素作回顾性单因素与多因素分析。单因素分

2、析采用Kaplan—Meier模型及Log—rank检验．多因素分析采用Cox比例风险模型。结果64例中晚期肝癌患者治疗后l、1．5、2年总生存率分别为75．8％、48．4％、33．9％。单因素分析及Cox回归分析结果显示肿瘤大小、肿瘤数目、门静脉癌栓、血清AFP值、肿瘤期别、服用索拉菲尼等6项因素与预后有关。结论肿瘤大小、肿瘤数目、门静脉癌栓、血清AFP值、肿瘤期别是影响介人综合治疗预后的危险因素，服用索拉菲尼是影响预后的保护性因素。【关键词】癌，肝细胞；化疗栓塞；微波消融；预后中图分类号：R735．7文献标志码：A文章编

3、号：1008—794X(2014)一06—0477—05TranscatheterarterjalchemoembolizationcombinedwititpercutaneousmicrowaveaMationforthetreatmentofintermediate—advancedhepatocellularcarcinoma：analysisofprognosticfactorsin64casesWANHao-guang，XUWei，XUHao，GUYu—ming，ZUMoo—heng，WANGYong，ZONGY

4、ing—ying．DepartmentoflnterventionalRadiology，AfiliatedHospitalofXuzhouMedicalCollege，Xuzhou，JiangsuProvince221002，ChinaCorrespondingauthor：XUWei，E—mail：xuweiO202@gmm1．com【Abstract】ObjectiveToinvestigatetheprognosticfactorsaffectingtheoutcomeofpatientswithintermedia

5、te—advancedhepatocellularcarcinoma(HCC)receivingtranseatheterarterialchemoembolization(TACE)combinedwithpercutaneousmicrowaveablation(MWA)．MethodsDuringtheperiodfromJanuary2011toJuly2012atauthors’hospita1．atota1of64patientswithintermediate-advancedHCCweretreatedwit

6、hTACEtogetherwithMWA．Fourteenpotentialvariableswhichmightaffecttheprognosiswerecolletedandwereretrospectivelyanalyzed．Kaplan-Meiermodelandlog—ranktestwereusedforsinglefactoranalysis，whileCoxregressionmodelwasusedformultiplefactoranalysis．ResultsTheone—year，1．5-year

7、and2-yearoverallsurvivalrateswere75．8％，48．4％and33．9％，respectively．SinglefactoranalysisandCoxregressionanalysisindicatedthatsixfactors，i．e．tumorsize，numberoftumors，portalveintumorthrombus，serlmoL—fetoproteinlevel，tumorstagingandoraladministrationofsorafenib，borearel

8、ationshiptotheprognosis．ConclusionThetumorsize，numberoftumors，portalveintumorthrombus，serumoL—fetoproteinlevelandtumorstagingareriskfactorsinflue